How Cambrian BioPharma is reinventing drug - and drug company - development

We're talking about developing therapeutics for anti-aging. Matt Burns interviewed James Peyer, the co-founder of Cambrian BioPharma, and Maryanna Saenko, co-founder and partner at Future Ventures. Cambrian BioPharma bills itself as a new pharmaceutical company with a revolutionary approach to developing and managing drug development and raised over $180 million to accelerate the development of medicine designed to target the causes of age-related diseases.